Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function
Yan Li,1 Xiaomin Wang,2 Edward O’Mara,1 Meletios A Dimopoulos,3 Pieter Sonneveld,4 Katja C Weisel,5 Jeffrey Matous,6 David S Siegel,7 Jatin J Shah,8 Elisabeth Kueenburg,9 Lars Sternas,9 Chloe Cavanaugh,9 Mohamed Zaki,9 Maria Palmisano,1 Simon Zhou1 1Translational Development and C...
Saved in:
Main Authors: | Li Y (Author), Wang X (Author), O'Mara E (Author), Dimopoulos MA (Author), Sonneveld P (Author), Weisel KC (Author), Matous J (Author), Siegel DS (Author), Shah JJ (Author), Kueenburg E (Author), Sternas L (Author), Cavanaugh C (Author), Zaki M (Author), Palmisano M (Author), Zhou S (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2017-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients-Real-World Data From Hungary
by: Szilvia Lovas, et al.
Published: (2022) -
PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA
by: M. Yu. Frolov, et al.
Published: (2017) -
Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
by: Rios-Tamayo R, et al.
Published: (2017) -
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
by: Joseph NS, et al.
Published: (2021) -
Pomalidomide enhances the maturation of dendritic cells derived from healthy donors and multiple myeloma patients
by: Xi Wang, et al.
Published: (2022)